Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Positron-Emission Tomography | 11 | 2022 | 100 | 3.110 |
Why?
|
| Radiopharmaceuticals | 12 | 2025 | 73 | 3.010 |
Why?
|
| Hippurates | 7 | 2018 | 25 | 3.000 |
Why?
|
| Radioisotope Renography | 7 | 2018 | 29 | 2.530 |
Why?
|
| Technetium | 6 | 2014 | 43 | 1.970 |
Why?
|
| Kidney | 5 | 2017 | 286 | 1.940 |
Why?
|
| Fluorine Radioisotopes | 7 | 2018 | 26 | 1.900 |
Why?
|
| CD13 Antigens | 5 | 2014 | 26 | 1.680 |
Why?
|
| Oligopeptides | 4 | 2014 | 97 | 1.540 |
Why?
|
| Iodohippuric Acid | 3 | 2018 | 9 | 1.420 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 4 | 2020 | 37 | 1.200 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 3 | 2017 | 8 | 1.190 |
Why?
|
| Glycine | 2 | 2017 | 31 | 0.990 |
Why?
|
| Coordination Complexes | 2 | 2017 | 27 | 0.980 |
Why?
|
| Succimer | 1 | 2025 | 2 | 0.960 |
Why?
|
| Drug Compounding | 1 | 2025 | 32 | 0.940 |
Why?
|
| Animals | 36 | 2022 | 10583 | 0.820 |
Why?
|
| Rats | 8 | 2018 | 1587 | 0.700 |
Why?
|
| Radiation Dosage | 2 | 2018 | 54 | 0.680 |
Why?
|
| Tissue Distribution | 10 | 2022 | 137 | 0.630 |
Why?
|
| Chemistry Techniques, Synthetic | 2 | 2017 | 10 | 0.620 |
Why?
|
| Peptides | 3 | 2021 | 293 | 0.570 |
Why?
|
| Absorption, Radiation | 1 | 2017 | 4 | 0.560 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2017 | 4 | 0.560 |
Why?
|
| Radiometry | 2 | 2017 | 45 | 0.550 |
Why?
|
| Technetium Tc 99m Mertiatide | 2 | 2018 | 4 | 0.500 |
Why?
|
| Onium Compounds | 1 | 2015 | 8 | 0.490 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2016 | 554 | 0.480 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2017 | 10 | 0.470 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2015 | 36 | 0.470 |
Why?
|
| Models, Biological | 1 | 2017 | 468 | 0.460 |
Why?
|
| Urothelium | 1 | 2014 | 35 | 0.430 |
Why?
|
| Biological Transport | 1 | 2014 | 124 | 0.430 |
Why?
|
| Disease Progression | 1 | 2015 | 475 | 0.420 |
Why?
|
| Mice | 20 | 2022 | 4735 | 0.410 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 79 | 0.410 |
Why?
|
| Fibrosarcoma | 1 | 2013 | 12 | 0.410 |
Why?
|
| Molecular Imaging | 1 | 2013 | 35 | 0.400 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2014 | 164 | 0.390 |
Why?
|
| Mice, Nude | 5 | 2014 | 332 | 0.380 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 108 | 0.380 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 40 | 0.380 |
Why?
|
| Molecular Structure | 7 | 2013 | 244 | 0.360 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 251 | 0.340 |
Why?
|
| Peptides, Cyclic | 1 | 2010 | 30 | 0.330 |
Why?
|
| Humans | 25 | 2021 | 28585 | 0.310 |
Why?
|
| Glioblastoma | 1 | 2010 | 109 | 0.300 |
Why?
|
| Cell Line, Tumor | 8 | 2017 | 1341 | 0.300 |
Why?
|
| Disease Models, Animal | 8 | 2020 | 1494 | 0.280 |
Why?
|
| Female | 17 | 2021 | 15472 | 0.280 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 351 | 0.270 |
Why?
|
| Enterotoxins | 2 | 2006 | 22 | 0.250 |
Why?
|
| Organ Specificity | 3 | 2017 | 82 | 0.240 |
Why?
|
| Nanoparticles | 3 | 2020 | 291 | 0.240 |
Why?
|
| Iodine Radioisotopes | 2 | 2018 | 36 | 0.230 |
Why?
|
| Glucaric Acid | 2 | 2022 | 10 | 0.220 |
Why?
|
| Prostatic Neoplasms | 3 | 2020 | 282 | 0.210 |
Why?
|
| Colonic Neoplasms | 3 | 2014 | 121 | 0.200 |
Why?
|
| Escherichia coli | 2 | 2006 | 338 | 0.200 |
Why?
|
| Fullerenes | 3 | 2007 | 4 | 0.200 |
Why?
|
| Neoplasms, Experimental | 2 | 2013 | 58 | 0.190 |
Why?
|
| Bombesin | 3 | 2011 | 10 | 0.190 |
Why?
|
| Disulfides | 1 | 2002 | 34 | 0.180 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 357 | 0.180 |
Why?
|
| Drug Stability | 2 | 2012 | 23 | 0.180 |
Why?
|
| Indium Radioisotopes | 4 | 2006 | 7 | 0.170 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2021 | 65 | 0.170 |
Why?
|
| Coronary Vessels | 1 | 2022 | 153 | 0.170 |
Why?
|
| Cerebral Infarction | 1 | 2020 | 26 | 0.170 |
Why?
|
| Ammonia | 1 | 2019 | 18 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 27 | 0.150 |
Why?
|
| Bacterial Toxins | 1 | 2002 | 269 | 0.150 |
Why?
|
| Receptors, Enterotoxin | 1 | 2018 | 5 | 0.150 |
Why?
|
| Cyclotrons | 2 | 2019 | 11 | 0.150 |
Why?
|
| Paracrine Communication | 1 | 2018 | 17 | 0.150 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 19 | 0.140 |
Why?
|
| Cyclic GMP | 1 | 2018 | 29 | 0.140 |
Why?
|
| Hormones | 1 | 2018 | 44 | 0.140 |
Why?
|
| Renal Agents | 1 | 2018 | 2 | 0.140 |
Why?
|
| Radiation Exposure | 1 | 2017 | 17 | 0.140 |
Why?
|
| Male | 9 | 2020 | 13772 | 0.140 |
Why?
|
| Monte Carlo Method | 1 | 2018 | 62 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 548 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 54 | 0.130 |
Why?
|
| Automation, Laboratory | 1 | 2017 | 4 | 0.130 |
Why?
|
| Stroke | 1 | 2020 | 256 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 141 | 0.130 |
Why?
|
| Carcinogenesis | 2 | 2014 | 81 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2017 | 191 | 0.130 |
Why?
|
| Autoantibodies | 2 | 2021 | 479 | 0.130 |
Why?
|
| Computer Simulation | 1 | 2017 | 231 | 0.130 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2016 | 16 | 0.120 |
Why?
|
| Halogenation | 1 | 2015 | 7 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2017 | 458 | 0.120 |
Why?
|
| Mice, Transgenic | 2 | 2014 | 509 | 0.120 |
Why?
|
| Mucin-1 | 1 | 2016 | 36 | 0.120 |
Why?
|
| Heterozygote | 1 | 2015 | 69 | 0.120 |
Why?
|
| Ornithine Decarboxylase | 2 | 1993 | 9 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 236 | 0.110 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2015 | 11 | 0.110 |
Why?
|
| Receptors, Bombesin | 3 | 2003 | 6 | 0.110 |
Why?
|
| Brain | 1 | 2020 | 753 | 0.110 |
Why?
|
| Acetates | 1 | 2014 | 45 | 0.110 |
Why?
|
| Vasoconstriction | 1 | 2015 | 45 | 0.110 |
Why?
|
| Radioisotopes | 1 | 2014 | 10 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 472 | 0.110 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 22 | 0.110 |
Why?
|
| Alanine | 1 | 2014 | 40 | 0.110 |
Why?
|
| Protein Binding | 4 | 2010 | 664 | 0.110 |
Why?
|
| Blood-Brain Barrier | 1 | 2014 | 83 | 0.110 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2014 | 8 | 0.110 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2014 | 8 | 0.110 |
Why?
|
| Estrogen Antagonists | 1 | 2014 | 16 | 0.110 |
Why?
|
| Amides | 1 | 2014 | 19 | 0.110 |
Why?
|
| Hepatocytes | 1 | 2014 | 80 | 0.110 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2014 | 37 | 0.110 |
Why?
|
| Quinolines | 1 | 2014 | 26 | 0.100 |
Why?
|
| Skin | 2 | 1993 | 151 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2015 | 355 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 59 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 64 | 0.100 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 61 | 0.100 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2013 | 4 | 0.100 |
Why?
|
| Chorioallantoic Membrane | 1 | 2013 | 7 | 0.100 |
Why?
|
| Chick Embryo | 1 | 2013 | 27 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 465 | 0.100 |
Why?
|
| Genotype | 1 | 2014 | 461 | 0.100 |
Why?
|
| Isotope Labeling | 2 | 2010 | 31 | 0.100 |
Why?
|
| Intestines | 1 | 2014 | 118 | 0.100 |
Why?
|
| Radiochemistry | 1 | 2012 | 10 | 0.100 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1993 | 31 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 164 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 278 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 124 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 275 | 0.090 |
Why?
|
| Hypertension | 1 | 2015 | 309 | 0.090 |
Why?
|
| Escherichia coli Proteins | 2 | 2004 | 118 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2018 | 1455 | 0.090 |
Why?
|
| Kidney Tubules | 1 | 2011 | 22 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2011 | 69 | 0.090 |
Why?
|
| Reference Standards | 1 | 2011 | 57 | 0.090 |
Why?
|
| Ellagic Acid | 1 | 1991 | 1 | 0.090 |
Why?
|
| Hydrolyzable Tannins | 1 | 1991 | 1 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2003 | 202 | 0.090 |
Why?
|
| Rhenium | 1 | 2011 | 5 | 0.090 |
Why?
|
| Gallic Acid | 1 | 1991 | 9 | 0.090 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 30 | 0.090 |
Why?
|
| Neoplasm Transplantation | 4 | 2006 | 90 | 0.090 |
Why?
|
| Mice, SCID | 4 | 2006 | 60 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 300 | 0.090 |
Why?
|
| Carbon Monoxide | 1 | 2011 | 47 | 0.090 |
Why?
|
| Necrosis | 2 | 2022 | 85 | 0.090 |
Why?
|
| Organometallic Compounds | 1 | 2011 | 42 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2015 | 131 | 0.090 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 31 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2006 | 103 | 0.080 |
Why?
|
| Amino Acid Motifs | 1 | 2010 | 66 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 2003 | 314 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2006 | 34 | 0.080 |
Why?
|
| Photosensitizing Agents | 2 | 2007 | 35 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 681 | 0.070 |
Why?
|
| Hydrogen Peroxide | 2 | 2022 | 145 | 0.070 |
Why?
|
| Singlet Oxygen | 1 | 2007 | 5 | 0.070 |
Why?
|
| Photochemotherapy | 1 | 2007 | 42 | 0.070 |
Why?
|
| Superoxides | 1 | 2007 | 62 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 78 | 0.060 |
Why?
|
| Chelating Agents | 1 | 2004 | 22 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2004 | 87 | 0.050 |
Why?
|
| Biomarkers | 2 | 2020 | 770 | 0.050 |
Why?
|
| Organotechnetium Compounds | 1 | 2003 | 2 | 0.050 |
Why?
|
| Streptavidin | 1 | 2022 | 11 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2002 | 62 | 0.050 |
Why?
|
| Fibronectins | 1 | 2022 | 28 | 0.050 |
Why?
|
| Receptors, LHRH | 1 | 2021 | 17 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 79 | 0.040 |
Why?
|
| Neoplasms | 2 | 2007 | 857 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 115 | 0.040 |
Why?
|
| Epitopes | 1 | 2021 | 185 | 0.040 |
Why?
|
| Perfusion | 1 | 2020 | 43 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 410 | 0.040 |
Why?
|
| Nitrogen Radioisotopes | 1 | 2019 | 5 | 0.040 |
Why?
|
| Spectrometry, Gamma | 1 | 2019 | 7 | 0.040 |
Why?
|
| Neutrophils | 1 | 2020 | 183 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 366 | 0.040 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 43 | 0.040 |
Why?
|
| Methanol | 1 | 2019 | 15 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 166 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2018 | 32 | 0.040 |
Why?
|
| Hemostasis | 1 | 2018 | 48 | 0.040 |
Why?
|
| Cytokines | 1 | 2020 | 448 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 74 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 17 | 0.030 |
Why?
|
| Chitosan | 1 | 2017 | 34 | 0.030 |
Why?
|
| Photochemistry | 2 | 2007 | 10 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 120 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 137 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 24 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 288 | 0.030 |
Why?
|
| Enzyme Induction | 2 | 1993 | 28 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 319 | 0.030 |
Why?
|
| Cross-Linking Reagents | 2 | 2006 | 42 | 0.030 |
Why?
|
| Rabbits | 1 | 2015 | 277 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 257 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2014 | 10 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2014 | 13 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 66 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 13 | 0.030 |
Why?
|
| Intestinal Neoplasms | 1 | 2014 | 15 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 23 | 0.030 |
Why?
|
| Terpenes | 1 | 1993 | 8 | 0.030 |
Why?
|
| Cell Count | 1 | 2014 | 86 | 0.030 |
Why?
|
| Carcinogens | 1 | 1993 | 39 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1993 | 611 | 0.030 |
Why?
|
| Mice, Inbred ICR | 2 | 2003 | 26 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 2003 | 56 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 782 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2011 | 45 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 70 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 96 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 178 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 132 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 222 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 551 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 333 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 452 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 1602 | 0.020 |
Why?
|
| Photobiology | 1 | 2007 | 2 | 0.020 |
Why?
|
| DNA Breaks | 1 | 2007 | 2 | 0.020 |
Why?
|
| Membranes | 1 | 2007 | 8 | 0.020 |
Why?
|
| Viruses | 1 | 2007 | 20 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2007 | 121 | 0.020 |
Why?
|
| Water | 1 | 2007 | 135 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 242 | 0.020 |
Why?
|
| Tolonium Chloride | 1 | 2005 | 2 | 0.020 |
Why?
|
| Cations | 1 | 2005 | 11 | 0.020 |
Why?
|
| Protein Renaturation | 1 | 2004 | 4 | 0.010 |
Why?
|
| Protein Denaturation | 1 | 2004 | 28 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2004 | 122 | 0.010 |
Why?
|
| Mutation | 1 | 2007 | 864 | 0.010 |
Why?
|
| Apoptosis | 1 | 2007 | 777 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2003 | 18 | 0.010 |
Why?
|
| Injections | 1 | 2003 | 31 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2003 | 209 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 123 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 695 | 0.010 |
Why?
|
| Xanthine Oxidase | 1 | 1993 | 5 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1993 | 8 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1993 | 74 | 0.010 |
Why?
|
| DNA | 1 | 1993 | 375 | 0.010 |
Why?
|